PURPOSE: An early and reliable blood test is one deficiency in diagnosis of malignant pleural mesothelioma (MPM). Megakaryocyte potentiating factor (MPF) and mesothelin variants (MSLN), members of the mesothelin gene family, have been studied as candidate serum markers for MPM. We developed a novel enzyme-linked immunosorbent assay (ELISA) system to compare the diagnostic efficacy of MPF and MSLN in MPM and control groups. EXPERIMENTAL DESIGN: MPF and MSLN were assayed with ELISA in 27 consecutive MPM patients and 129 controls including patients with lung cancer and asymptomatic asbestos-exposed subjects. RESULTS: Statistically significant elevation of serum MPF and MSLN levels was noted in MPM patients in comparison with every control group. The area under the receiver operating characteristic curve (AUC) was calculated for differentiation of MPM and lung cancer, healthy asbestos-exposed subjects, and healthy adults. While the AUC for serum MPF was 0.879, cut-off=19.1ng/ml (sensitivity=74.1%, specificity=90.4%), the AUC for serum MSLN was 0.713, cut-off=93.5ng/ml (sensitivity=59.3%, specificity=86.2%). Comparison between AUC for MPF and MSLN values shows that MPF is significantly superior to MSLN (p=0.025). Finally, there was a significant correlation between MPF and MSLN values for MPM (Pearson's correlation coefficient=0.77; p<0.001). CONCLUSIONS: These findings suggest that diagnostic value of MPF for MPM was better than that of MSLN although both markers showed almost equal specificity for MPM.
PURPOSE: An early and reliable blood test is one deficiency in diagnosis of malignant pleural mesothelioma (MPM). Megakaryocyte potentiating factor (MPF) and mesothelin variants (MSLN), members of the mesothelin gene family, have been studied as candidate serum markers for MPM. We developed a novel enzyme-linked immunosorbent assay (ELISA) system to compare the diagnostic efficacy of MPF and MSLN in MPM and control groups. EXPERIMENTAL DESIGN:MPF and MSLN were assayed with ELISA in 27 consecutive MPM patients and 129 controls including patients with lung cancer and asymptomatic asbestos-exposed subjects. RESULTS: Statistically significant elevation of serum MPF and MSLN levels was noted in MPM patients in comparison with every control group. The area under the receiver operating characteristic curve (AUC) was calculated for differentiation of MPM and lung cancer, healthy asbestos-exposed subjects, and healthy adults. While the AUC for serum MPF was 0.879, cut-off=19.1ng/ml (sensitivity=74.1%, specificity=90.4%), the AUC for serum MSLN was 0.713, cut-off=93.5ng/ml (sensitivity=59.3%, specificity=86.2%). Comparison between AUC for MPF and MSLN values shows that MPF is significantly superior to MSLN (p=0.025). Finally, there was a significant correlation between MPF and MSLN values for MPM (Pearson's correlation coefficient=0.77; p<0.001). CONCLUSIONS: These findings suggest that diagnostic value of MPF for MPM was better than that of MSLN although both markers showed almost equal specificity for MPM.
Authors: Elad Sharon; Jingli Zhang; Kevin Hollevoet; Seth M Steinberg; Ira Pastan; Masanori Onda; Jochen Gaedcke; B Michael Ghadimi; Thomas Ried; Raffit Hassan Journal: Clin Chem Lab Med Date: 2012-04 Impact factor: 3.694
Authors: Carmina Jiménez-Ramírez; Swaantje Casjens; Cuauhtémoc Arturo Juárez-Pérez; Irina Raiko; Luz M Del Razo; Dirk Taeger; Emma S Calderón-Aranda; Hans-Peter Rihs; Leonor Concepción Acosta-Saavedra; Daniel Gilbert Weber; Alejandro Cabello-López; Beate Pesch; María Dolores Ochoa-Vázquez; Katarzyna Burek; Luis Torre-Bouscoulet; José Rogelio Pérez-Padilla; Erik Marco García-Bazan; Thomas Brüning; Georg Johnen; Guadalupe Aguilar-Madrid Journal: Lung Date: 2019-07-02 Impact factor: 2.584
Authors: Clementina Mesaros; Andrew J Worth; Nathaniel W Snyder; Melpo Christofidou-Solomidou; Anil Vachani; Steven M Albelda; Ian A Blair Journal: Bioanalysis Date: 2015 Impact factor: 2.681
Authors: Raffit Hassan; Hedy L Kindler; Thierry Jahan; Lyudmila Bazhenova; Martin Reck; Anish Thomas; Ira Pastan; Jeff Parno; Daniel J O'Shannessy; Penny Fatato; Julia D Maltzman; Bruce A Wallin Journal: Clin Cancer Res Date: 2014-09-17 Impact factor: 12.531
Authors: Kevin Hollevoet; Johannes B Reitsma; Jenette Creaney; Bogdan D Grigoriu; Bruce W Robinson; Arnaud Scherpereel; Alfonso Cristaudo; Harvey I Pass; Kristiaan Nackaerts; José A Rodríguez Portal; Joachim Schneider; Thomas Muley; Francesca Di Serio; Paul Baas; Marco Tomasetti; Alex J Rai; Jan P van Meerbeeck Journal: J Clin Oncol Date: 2012-03-12 Impact factor: 44.544